Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Benjamin H Durham, Michael E Singer, Salima Benbarche, Caroline Erickson, Jahan Rahman, David B. Solit, Matthew Witkowski, Neal Rosen, Omar Abdel-Wahab, Eli L Diamond

Blood (2022) 140 (Supplement 1): 1098–1100.

https://doi.org/10.1182/blood-2022-163575

Published: 2022

Journal Articles

Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation

Blood (2021) 138 (Supplement 1): 356.

https://doi.org/10.1182/blood-2021-147026

Published: 2021

Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Benjamin Heath Durham, MD BS, Eli L. Diamond, MD, Julien Haroche, MD PhD, Zhan Yao, PhD, Jing Ma, PhD, Sameer A. Parikh, MD, John Choi, Eunhee Kim, PhD, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, MD, Patrick Campbell, MD PhD, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Aminova Olga, Adriana Heguy, Paul Zappile, Joy Nakitandwe, BSc,MSc,PhD, James Dalton, BS, David W Ellison, MD, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, MD PhD, Phil Stephens, PhD, Vincent A. Miller, MD, Jeffrey Ross, Siraj Ali, Sebastien Héritier, Jean Donadieu, MD PhD, David Solit, MD, David M. Hyman, Jose Baselga, MD PhD, Filip Janku, MDPhD, Barry S. Taylor, PhD, Christopher Y. Park, MD, PhD, Ahmet Dogan, MD PhD, Zahir Amoura, Jean-Francois Emile, Raajit K. Rampal, MD, PhD, Neal Rosen, MD PhD, Tanja A. Gruber, MD PhD, Omar Abdel-Wahab

Blood (2015) 126 (23): 481.

https://doi.org/10.1182/blood.V126.23.481.481

Published: 2015

Journal Articles

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Benjamin Durham, MD PhD, Young Rock Chung, MS, Sasinya Scott, MPH, Bartlomiej Getta, MBBS,, Eunhee Kim, PhD, Alan Saven, MD, Richard M. Stone, MD, Kanti R Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Neal Rosen, MD PhD, Ross L. Levine, MD, Michael Berger, PhD, Martin S Tallman, MD, Omar Abdel-Wahab

Blood (2015) 126 (23): 449.

https://doi.org/10.1182/blood.V126.23.449.449

Published: 2015

Journal Articles

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MS, Helen Won, MS, Eunhee Kim, PhD, Alan Saven, MD, Martha Wadleigh, MD, Richard M. Stone, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Mario E Lacouture, MD, Neal Rosen, MD PhD, Michael Berger, PhD, Ross L Levine, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 24.

https://doi.org/10.1182/blood.V124.21.24.24

Published: 2014

Journal Articles

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

Stephen S. Chung, MD, Jae H. Park, MD, Eunhee Kim, PhD, Young Rock Chung, MSc, Wenhuo Hu, PhD, Piro Lito, MD, PhD, Julie Teruya Feldstein, MD, Raajit K. Rampal, M.D., Ph.D., Leon Telis, Minal Patel, Neal Rosen, Christopher Y. Park, M.D., Ph.D., Martin S. Tallman, MD, Omar Abdel-Wahab, MD

Blood (2013) 122 (21): 816.

https://doi.org/10.1182/blood.V122.21.816.816

Published: 2013

Journal Articles

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90

Mercedes E. Gorre, Katharine Ellwood-Yen, Gabriela Chiosis, Neal Rosen, Charles L. Sawyers

Blood (2002) 100 (8): 3041–3044.

https://doi.org/10.1182/blood-2002-05-1361

Published: 2002

NARROW

RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90

Email alerts

ASH Publications

American Society of Hematology

RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Impaired RAS Proteolysis Drives Clonal Hematopoietic Transformation

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

BRAF V600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia

BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only